{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:38:03Z","timestamp":1778747883366,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jgisurgery.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s11605-016-3194-z","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T17:03:12Z","timestamp":1468342992000},"page":"1636-1642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience"],"prefix":"10.1016","volume":"20","author":[{"given":"Chaya","family":"Shwaartz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam C.","family":"Fields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximiliano","family":"Sobrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia M.","family":"Divino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s11605-016-3194-z_bb0010","doi-asserted-by":"crossref","unstructured":"Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflammatory bowel diseases. 2007;13(6):769-96. doi:10.1002\/ibd.20027.","DOI":"10.1002\/ibd.20027"},{"key":"10.1007\/s11605-016-3194-z_bb0015","doi-asserted-by":"crossref","unstructured":"Reenaers C, Louis E, Belaiche J. Current directions of biologic therapies in inflammatory bowel disease. Therapeutic advances in gastroenterology. 2010;3(2):99-106. doi:10.1177\/1756283x09356872.","DOI":"10.1177\/1756283X09356872"},{"key":"10.1007\/s11605-016-3194-z_bb0020","doi-asserted-by":"crossref","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. The New England journal of medicine. 2005;353(23):2462-76. doi:10.1056\/NEJMoa050516.","DOI":"10.1056\/NEJMoa050516"},{"issue":"2","key":"10.1007\/s11605-016-3194-z_bb0025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1007\/s11605-016-3194-z_bb0030","unstructured":"Loftus EV, Jr. Progress in the diagnosis and treatment of inflammatory bowel disease. Gastroenterology & hepatology. 2011;7(2 Suppl 3):3-16."},{"key":"10.1007\/s11605-016-3194-z_bb0035","doi-asserted-by":"crossref","unstructured":"Alexakis C, Pollok RC. Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis. World journal of gastrointestinal surgery. 2015;7(12):360-9. doi:10.4240\/wjgs.v7.i12.360.","DOI":"10.4240\/wjgs.v7.i12.360"},{"issue":"5","key":"10.1007\/s11605-016-3194-z_bb0040","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","article-title":"Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies","volume":"145","author":"Frolkis","year":"2013","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1007\/s11605-016-3194-z_bb0045","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/gutjnl-2013-305607","article-title":"Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011","volume":"63","author":"Rungoe","year":"2014","journal-title":"Gut"},{"key":"10.1007\/s11605-016-3194-z_bb0050","doi-asserted-by":"crossref","unstructured":"Holubar SD, Holder-Murray J, Flasar M, Lazarev M. Anti-Tumor Necrosis Factor-alpha Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper. Inflammatory bowel diseases. 2015;21(11):2658-72. doi:10.1097\/mib.0000000000000603.","DOI":"10.1097\/MIB.0000000000000603"},{"key":"10.1007\/s11605-016-3194-z_bb0055","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D et al. Certolizumab pegol for the treatment of Crohn\u2019s disease. The New England journal of medicine. 2007;357(3):228-38. doi:10.1056\/NEJMoa067594.","DOI":"10.1056\/NEJMoa067594"},{"issue":"9317","key":"10.1007\/s11605-016-3194-z_bb0060","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet (London, England)"},{"key":"10.1007\/s11605-016-3194-z_bb0065","doi-asserted-by":"crossref","unstructured":"Shetty A, Forbes A. Pharmacogenomics of response to anti-tumor necrosis factor therapy in patients with Crohn\u2019s disease. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2002;2(4):215-21.","DOI":"10.2165\/00129785-200202040-00001"},{"key":"10.1007\/s11605-016-3194-z_bb0070","doi-asserted-by":"crossref","unstructured":"Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn\u2019s disease. Expert opinion on drug safety. 2016. doi:10.1517\/14740338.2016.1145653.","DOI":"10.1517\/14740338.2016.1145653"},{"key":"10.1007\/s11605-016-3194-z_bb0075","doi-asserted-by":"crossref","unstructured":"Albina JE, Mastrofrancesco B, Vessella JA, Louis CA, Henry WL, Jr., Reichner JS. HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-alpha. American journal of physiology Cell physiology. 2001;281(6):C1971-7.","DOI":"10.1152\/ajpcell.2001.281.6.C1971"},{"key":"10.1007\/s11605-016-3194-z_bb0080","doi-asserted-by":"crossref","unstructured":"Lee RH, Efron DT, Tantry U, Stuelten C, Moldawer LL, Abouhamze A et al. Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2000;8(6):547-53.","DOI":"10.1046\/j.1524-475x.2000.00547.x"},{"key":"10.1007\/s11605-016-3194-z_bb0085","doi-asserted-by":"crossref","unstructured":"Salomon GD, Kasid A, Cromack DT, Director E, Talbot TL, Sank A et al. The local effects of cachectin\/tumor necrosis factor on wound healing. Annals of surgery. 1991;214(2):175-80.","DOI":"10.1097\/00000658-199108000-00012"},{"key":"10.1007\/s11605-016-3194-z_bb0090","doi-asserted-by":"crossref","unstructured":"Papaconstantinou I, Zeglinas C, Gazouli M, Nastos K, Yiallourou A, Papalois A et al. The impact of peri-operative anti-TNF treatment on anastomosis-related complications in Crohn\u2019s disease patients. A critical review. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2014;18(6):1216-24. doi:10.1007\/s11605-014-2487-3.","DOI":"10.1007\/s11605-014-2487-3"},{"key":"10.1007\/s11605-016-3194-z_bb0095","doi-asserted-by":"crossref","unstructured":"Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH. Anti-tumor necrosis factor and postoperative complications in Crohn\u2019s disease: systematic review and meta-analysis. Inflammatory bowel diseases. 2012;18(12):2404-13. doi:10.1002\/ibd.22954.","DOI":"10.1002\/ibd.22954"},{"key":"10.1007\/s11605-016-3194-z_bb0100","doi-asserted-by":"crossref","unstructured":"Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn\u2019s patients. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2008;12(10):1738-44. doi:10.1007\/s11605-008-0646-0.","DOI":"10.1007\/s11605-008-0646-0"},{"key":"10.1007\/s11605-016-3194-z_bb0105","doi-asserted-by":"crossref","unstructured":"Serradori T, Germain A, Scherrer ML, Ayav C, Perez M, Romain B et al. The effect of immune therapy on surgical site infection following Crohn\u2019s Disease resection. The British journal of surgery. 2013;100(8):1089-93. doi:10.1002\/bjs.9152.","DOI":"10.1002\/bjs.9152"},{"key":"10.1007\/s11605-016-3194-z_bb0110","doi-asserted-by":"crossref","unstructured":"Lau C, Dubinsky M, Melmed G, Vasiliauskas E, Berel D, McGovern D et al. The impact of preoperative serum anti-TNFalpha therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Annals of surgery. 2015;261(3):487-96. doi:10.1097\/sla.0000000000000757.","DOI":"10.1097\/SLA.0000000000000757"},{"key":"10.1007\/s11605-016-3194-z_bb0115","doi-asserted-by":"crossref","unstructured":"Syed A, Cross RK, Flasar MH. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn\u2019s disease patients. The American journal of gastroenterology. 2013;108(4):583-93. doi:10.1038\/ajg.2012.464.","DOI":"10.1038\/ajg.2012.464"},{"key":"10.1007\/s11605-016-3194-z_bb0120","doi-asserted-by":"crossref","unstructured":"Kasparek MS, Bruckmeier A, Beigel F, Muller MH, Brand S, Mansmann U et al. Infliximab does not affect postoperative complication rates in Crohn\u2019s patients undergoing abdominal surgery. Inflammatory bowel diseases. 2012;18(7):1207-13. doi:10.1002\/ibd.21860.","DOI":"10.1002\/ibd.21860"},{"key":"10.1007\/s11605-016-3194-z_bb0125","doi-asserted-by":"crossref","unstructured":"Rizzo G, Armuzzi A, Pugliese D, Verbo A, Papa A, Mattana C et al. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. International journal of colorectal disease. 2011;26(11):1435-44. doi:10.1007\/s00384-011-1236-2.","DOI":"10.1007\/s00384-011-1236-2"},{"key":"10.1007\/s11605-016-3194-z_bb0130","doi-asserted-by":"crossref","unstructured":"Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Alimentary pharmacology & therapeutics. 2012;36(10):922-8. doi:10.1111\/apt.12060.","DOI":"10.1111\/apt.12060"},{"key":"10.1007\/s11605-016-3194-z_bb0135","doi-asserted-by":"crossref","unstructured":"Colombel JF, Loftus EV, Jr., Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T et al. Early postoperative complications are not increased in patients with Crohn\u2019s disease treated perioperatively with infliximab or immunosuppressive therapy. The American journal of gastroenterology. 2004;99(5):878-83. doi:10.1111\/j.1572-0241.2004.04148.x.","DOI":"10.1111\/j.1572-0241.2004.04148.x"},{"issue":"5","key":"10.1007\/s11605-016-3194-z_bb0140","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jamcollsurg.2006.12.044","article-title":"Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis","volume":"204","author":"Selvasekar","year":"2007","journal-title":"Journal of the American College of Surgeons"},{"key":"10.1007\/s11605-016-3194-z_bb0145","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflammatory bowel diseases. 1999;5(2):119-33.","DOI":"10.1097\/00054725-199905000-00008"},{"key":"10.1007\/s11605-016-3194-z_bb0150","doi-asserted-by":"crossref","unstructured":"Cornillie F, Shealy D, D\u2019Haens G, Geboes K, Van Assche G, Ceuppens J et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn\u2019s disease. Alimentary pharmacology & therapeutics. 2001;15(4):463-73.","DOI":"10.1046\/j.1365-2036.2001.00956.x"},{"key":"10.1007\/s11605-016-3194-z_bb0155","doi-asserted-by":"crossref","unstructured":"Canedo J, Lee SH, Pinto R, Murad-Regadas S, Rosen L, Wexner SD. Surgical resection in Crohn\u2019s disease: is immunosuppressive medication associated with higher postoperative infection rates? Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2011;13(11):1294-8. doi:10.1111\/j.1463-1318.2010.02469.x.","DOI":"10.1111\/j.1463-1318.2010.02469.x"},{"issue":"3","key":"10.1007\/s11605-016-3194-z_bb0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gutjnl-2011-301495","article-title":"Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease","volume":"62","author":"Waterman","year":"2013","journal-title":"Gut"},{"key":"10.1007\/s11605-016-3194-z_bb0165","doi-asserted-by":"crossref","unstructured":"Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ et al. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn\u2019s disease. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2010;14(12):1859-65; discussion 65-6. doi:10.1007\/s11605-010-1341-5.","DOI":"10.1007\/s11605-010-1341-5"},{"key":"10.1007\/s11605-016-3194-z_bb0170","doi-asserted-by":"crossref","unstructured":"Norgard BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-alpha agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study. Alimentary pharmacology & therapeutics. 2012;35(11):1301-9. doi:10.1111\/j.1365-2036.2012.05099.x.","DOI":"10.1111\/j.1365-2036.2012.05099.x"},{"issue":"2","key":"10.1007\/s11605-016-3194-z_bb0175","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0016-5085(03)00883-7","article-title":"Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients","volume":"125","author":"Aberra","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1007\/s11605-016-3194-z_bb0180","doi-asserted-by":"crossref","unstructured":"Nguyen GC, Elnahas A, Jackson TD. The impact of preoperative steroid use on short-term outcomes following surgery for inflammatory bowel disease. Journal of Crohn\u2019s & colitis. 2014;8(12):1661-7. doi:10.1016\/j.crohns.2014.07.007.","DOI":"10.1016\/j.crohns.2014.07.007"},{"key":"10.1007\/s11605-016-3194-z_bb0185","doi-asserted-by":"crossref","unstructured":"Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. The American journal of gastroenterology. 2008;103(9):2373-81. doi:10.1111\/j.1572-0241.2008.01942.x.","DOI":"10.1111\/j.1572-0241.2008.01942.x"},{"key":"10.1007\/s11605-016-3194-z_bb0190","doi-asserted-by":"crossref","unstructured":"Tzivanakis A, Singh JC, Guy RJ, Travis SP, Mortensen NJ, George BD. Influence of risk factors on the safety of ileocolic anastomosis in Crohn\u2019s disease surgery. Diseases of the colon and rectum. 2012;55(5):558-62. doi:10.1097\/DCR.0b013e318247c433.","DOI":"10.1097\/DCR.0b013e318247c433"},{"key":"10.1007\/s11605-016-3194-z_bb0195","doi-asserted-by":"crossref","unstructured":"Midura EF, Hanseman D, Davis BR, Atkinson SJ, Abbott DE, Shah SA et al. Risk factors and consequences of anastomotic leak after colectomy: a national analysis. Diseases of the colon and rectum. 2015;58(3):333-8. doi:10.1097\/dcr.0000000000000249.","DOI":"10.1097\/DCR.0000000000000249"},{"issue":"3","key":"10.1007\/s11605-016-3194-z_bb0200","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jamcollsurg.2005.10.019","article-title":"Risk factors for anastomotic leakage after surgery for colorectal cancer: results of prospective surveillance","volume":"202","author":"Konishi","year":"2006","journal-title":"Journal of the American College of Surgeons"},{"key":"10.1007\/s11605-016-3194-z_bb0205","doi-asserted-by":"crossref","unstructured":"Mahadevan U, Loftus EV, Jr., Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflammatory bowel diseases. 2002;8(5):311-6.","DOI":"10.1097\/00054725-200209000-00001"},{"key":"10.1007\/s11605-016-3194-z_bb0210","doi-asserted-by":"crossref","unstructured":"Bafford AC, Powers S, Ha C, Kruse D, Gorfine SR, Chessin DB et al. Immunosuppressive therapy does not increase operative morbidity in patients with Crohn\u2019s disease. Journal of clinical gastroenterology. 2013;47(6):491-5. doi:10.1097\/MCG.0b013e3182677003.","DOI":"10.1097\/MCG.0b013e3182677003"},{"key":"10.1007\/s11605-016-3194-z_bb0215","doi-asserted-by":"crossref","unstructured":"Resegotti A, Astegiano M, Farina EC, Ciccone G, Avagnina G, Giustetto A et al. Side-to-side stapled anastomosis strongly reduces anastomotic leak rates in Crohn\u2019s disease surgery. Diseases of the colon and rectum. 2005;48(3):464-8. doi:10.1007\/s10350-004-0786-6.","DOI":"10.1007\/s10350-004-0786-6"},{"key":"10.1007\/s11605-016-3194-z_bb0220","doi-asserted-by":"crossref","unstructured":"Korolija D. The current evidence on stapled versus hand-sewn anastomoses in the digestive tract. Minimally invasive therapy & allied technologies: MITAT: official journal of the Society for Minimally Invasive Therapy. 2008;17(3):151-4. doi:10.1080\/13645700802103423.","DOI":"10.1080\/13645700802103423"},{"key":"10.1007\/s11605-016-3194-z_bb0225","doi-asserted-by":"crossref","unstructured":"Markides GA, Wijetunga I, McMahon M, Gupta P, Subramanian A, Anwar S. Reversal of loop ileostomy under an Enhanced Recovery Programme\u2014Is the stapled anastomosis technique still better than the handsewn technique? International journal of surgery (London, England). 2015;23(Pt A):41-5. doi:10.1016\/j.ijsu.2015.09.039.","DOI":"10.1016\/j.ijsu.2015.09.039"},{"key":"10.1007\/s11605-016-3194-z_bb0230","doi-asserted-by":"crossref","unstructured":"Farrah JP, Lauer CW, Bray MS, McCartt JM, Chang MC, Meredith JW et al. Stapled versus hand-sewn anastomoses in emergency general surgery: a retrospective review of outcomes in a unique patient population. The journal of trauma and acute care surgery. 2013;74(5):1187-92; discussion 92-4. doi:10.1097\/TA.0b013e31828cc9c4.","DOI":"10.1097\/TA.0b013e31828cc9c4"},{"key":"10.1007\/s11605-016-3194-z_bb0235","doi-asserted-by":"crossref","unstructured":"Loffler T, Rossion I, Goossen K, Saure D, Weitz J, Ulrich A et al. Hand suture versus stapler for closure of loop ileostomy--a systematic review and meta-analysis of randomized controlled trials. Langenbeck\u2019s archives of surgery\/Deutsche Gesellschaft fur Chirurgie. 2015;400(2):193-205. doi:10.1007\/s00423-014-1265-8.","DOI":"10.1007\/s00423-014-1265-8"},{"key":"10.1007\/s11605-016-3194-z_bb0240","doi-asserted-by":"crossref","unstructured":"McLeod RS, Wolff BG, Ross S, Parkes R, McKenzie M. Recurrence of Crohn\u2019s disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Diseases of the colon and rectum. 2009;52(5):919-27. doi:10.1007\/DCR.0b013e3181a4fa58.","DOI":"10.1007\/DCR.0b013e3181a4fa58"},{"key":"10.1007\/s11605-016-3194-z_bb0245","doi-asserted-by":"crossref","unstructured":"Indar AA, Young-Fadok TM, Heppell J, Efron JE. Effect of perioperative immunosuppressive medication on early outcome in Crohn\u2019s disease patients. World journal of surgery. 2009;33(5):1049-52. doi:10.1007\/s00268-009-9957-x.","DOI":"10.1007\/s00268-009-9957-x"},{"key":"10.1007\/s11605-016-3194-z_bb0250","doi-asserted-by":"crossref","unstructured":"Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Seminars in arthritis and rheumatism. 2005;34(5 Suppl1):12-8. doi:10.1016\/j.semarthrit.2005.01.004.","DOI":"10.1016\/j.semarthrit.2005.01.004"},{"key":"10.1007\/s11605-016-3194-z_bb0255","doi-asserted-by":"crossref","unstructured":"Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Current opinion in pharmacology. 2010;10(3):308-15. doi:10.1016\/j.coph.2010.01.005.","DOI":"10.1016\/j.coph.2010.01.005"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11605-016-3194-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11605-016-3194-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X23066970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X23066970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11605-016-3194-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T19:49:58Z","timestamp":1761076198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X23066970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1091255X23066970"],"URL":"https:\/\/doi.org\/10.1007\/s11605-016-3194-z","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s11605-016-3194-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Society for Surgery of the Alimentary Tract. Published by ELSEVIER INC. All rights reserved. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}